Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, cross-over study analyzing optimization of Albuminuria lowering treatment by rotation to different drug classes

Next Previous
Trial Profile

A randomized, cross-over study analyzing optimization of Albuminuria lowering treatment by rotation to different drug classes

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary) ; Empagliflozin (Primary) ; Linagliptin (Primary) ; Telmisartan (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Therapeutic Use

Most Recent Events

  • 18 Jan 2023 Results published in the Diabetes Care
  • 29 Jul 2022 New trial record
  • 07 Jun 2022 Primary endpoint has been met. (difference in UACR response between the first and second exposure to the best performing drug, versus the difference in UACR response between the best performing drug and the other three drugs),as per Results presented at the 82nd Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top